Charles River Laboratories Intl (CRL) Stock Price, Quote & News

Company Profile

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, includi...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 781 222 6000

Website: www.criver.com

Address:

251 Ballardvale Street, Wilmington, United States

OpenOutcrier Aug. 5 at 12:35 PM

$CRL (+8.1% pre) Charles River Labs stock climbs 8% on Q2 beat, raised guidance https://ooc.bz/l/109970

0 · Reply

flychicken1991 Aug. 5 at 12:27 PM

$CRL Positive (82%): CRL’s stock is likely to face upward pressure because higher 2026 guidance supports stronger forward earnings and cash-flow expectations, although falling quarterly earnings and revenue could limit the gain. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/1466346ecb0fc797?utm_source=stocktwits&utm_medium=story_url

0 · Reply

StocktwitsEarnings Aug. 5 at 11:21 AM

$CRL Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.03 down -102.83% YoY • Reported revenue of $1B down -2.72% YoY • Charles River Laboratories is increasing its 2026 revenue and non-GAAP earnings per share guidance, reflecting operational outperformance, while reducing GAAP earnings per share guidance due to net loss from divestitures.

0 · Reply

Bloodmooncapital Aug. 5 at 1:14 AM

$CRL

0 · Reply

IN0V8 Jul. 9 at 5:32 PM

$CRL Opportunity Morgan Stanley raises PT to $260.00 from $220.00

0 · Reply

Fingerlickengood Jun. 17 at 5:33 PM

$CDXS This is interesting, ST Pharm partnering with Vigen, owned by Charles River Labratories $CRL , for CDMO manufacturing in the US! My question is, will Codexis be involved in this partnership potentially? https://www.asiae.co.kr/en/article/bio-health/2026061710572918087

3 · Reply

briefingcom Jun. 17 at 12:43 PM

$CRL: Charles River Laboratories (+3.6%) upgraded to Overweight from Equal Weight at Morgan Stanley, tgt $220 https://www.briefing.com/calendars/updown?Filter=All&utm_campaign=updown&utm_medium=social&utm_source=st&utm_content=link

0 · Reply

Estimize May. 27 at 1:03 PM

Wall St is expecting 2.73 EPS for $CRL Q2 [Reporting 08/12 BMO] http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_cont

0 · Reply

YouOnlyLiveTwice May. 15 at 4:20 PM

$TMO $CRL What’s even more concerning besides that this space being bearish w these stocks trading at 5 year lows and NO CONSOLIDATION…

0 · Reply

YouOnlyLiveTwice May. 13 at 2:02 PM

$CRL $TMO These o my one that has growth in excess of 7% is RVTY and the only one w cloud based AI technology

0 · Reply

Charles River Laboratories International Earnings release: Q2 2026

Aug 5, 2026, 9:00 AM EDT - 35 minutes ago

Charles River Laboratories International Slides: Q2 2026

Aug 5, 2026, 7:38 AM EDT - 1 hour ago

Charles River lifts profit forecast on improving biotech demand

Aug 5, 2026, 7:00 AM EDT - 2 hours ago

Charles River Laboratories Announces Second-Quarter 2026 Results

2026-07-20T09:10:28.000Z - 16 days ago

Charles River downgraded to Hold from Outperform at CLSA

Jul 15, 2026, 8:00 AM EDT - 21 days ago

Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call

2026-07-13T12:05:13.000Z - 23 days ago

Charles River announces collaboration with Arovella Therapeutics

Jul 13, 2026, 8:00 AM EDT - 23 days ago

Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches

2026-07-13T11:45:31.000Z - 23 days ago

Charles River price target raised to $230 from $192 at Mizuho

2026-07-09T11:00:44.000Z - 27 days ago

Charles River price target raised to $260 from $220 at Morgan Stanley

2026-07-08T10:50:31.000Z - 4 weeks ago

Citi adds ‘upside 90-day catalyst watch’ on Charles River

Jul 3, 2026, 12:25 PM EDT - 4 weeks ago

Did Charles River Laboratories International, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

2026-06-18T12:19:05.000Z - 6 weeks ago

Charles River to collaborate with AI/ML drug discovery platform Lilly TuneLab

LLY

Jun 18, 2026, 8:00 AM EDT - 6 weeks ago

Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise

Jun 17, 2026, 12:30 PM EDT - 6 weeks ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX

2026-06-17T10:37:07.000Z - 7 weeks ago

Charles River upgraded to Overweight from Equal Weight at Morgan Stanley

Jun 3, 2026, 9:55 AM EDT - 2 months ago

Charles River Laboratories International Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 8:30 AM EDT - 2 months ago

Charles River Associates (CRA) to Present at the Sidoti Small-Cap Virtual Conference

Jun 2, 2026, 11:00 AM EDT - 2 months ago

Charles River Laboratories International Transcript: 46th Annual William Blair Growth Stock Conference

Jun 2, 2026, 11:00 AM EDT - 2 months ago

Charles River Laboratories International Slides: 46th Annual William Blair Growth Stock Conference

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Charles River Laboratories to Present at William Blair and Jefferies Conferences

2026-05-29T08:41:22.000Z - 2 months ago

Charles River upgraded to Outperform from Hold at CLSA

May 26, 2026, 8:30 AM EDT - 2 months ago

Charles River Associates (CRA) to Present at Noble Capital Markets Virtual Conference

2026-05-13T16:43:12.000Z - 2 months ago

Charles River, Medipost sign non-exclusive MoU to advance GMP testing solutions

May 13, 2026, 8:00 AM EDT - 3 months ago

Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions

2026-05-11T15:58:54.000Z - 3 months ago

Charles River announces ‘continued momentum’ in digital pathology platform

May 11, 2026, 8:00 AM EDT - 3 months ago

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

2026-05-08T18:35:02.000Z - 3 months ago

Charles River price target raised to $220 from $200 at Evercore ISI

2026-05-08T16:50:05.000Z - 3 months ago

Charles River price target raised to $213 from $200 at Baird

May 7, 2026, 8:30 AM EDT - 3 months ago

Charles River Laboratories International Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Charles River Laboratories International Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Charles River Laboratories International Slides: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Charles River Laboratories International Quarterly report: Q1 2026

May 7, 2026, 8:05 AM EDT - 3 months ago

Charles River Associates (CRA) Reports Financial Results for the First Quarter of 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Charles River Associates (CRA) Declares Quarterly Cash Dividend of $0.57 Per Common Share

May 7, 2026, 7:54 AM EDT - 3 months ago

Charles River beats quarterly estimates on steady demand for drug development services

May 7, 2026, 7:00 AM EDT - 3 months ago

Charles River Laboratories Announces First-Quarter 2026 Results

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Charles River Launches Rat In Vitro Fertility Services Demonstrating Embryology Capabilities

Apr 23, 2026, 8:30 AM EDT - 3 months ago

Charles River Associates (CRA) to Host First-Quarter Fiscal 2026 Financial Results Conference Call on May 7

Apr 21, 2026, 8:00 AM EDT - 3 months ago

Charles River Highlights Effectiveness of VCGs in Toxicology

Apr 16, 2026, 8:00 AM EDT - 3 months ago

Charles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call

Apr 13, 2026, 11:41 AM EDT - 4 months ago

Earnings Season Is Here. Microsoft and 7 More Companies That Usually Deliver.

MSFT ADBE APH BSX INTU NVDA WDAY

Apr 9, 2026, 4:30 PM EDT - 4 months ago

Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Association

Apr 6, 2026, 8:55 AM EDT - 4 months ago

NYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanX

Mar 31, 2026, 8:00 AM EDT - 4 months ago

Charles River Laboratories International Proxy statement: Proxy filing

Mar 10, 2026, 10:00 AM EDT - 5 months ago

Charles River Laboratories International Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 3, 2026, 9:50 AM EST - 5 months ago

Charles River Laboratories International Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 8:00 AM EST - 5 months ago

Charles River Laboratories to Present at TD Cowen and Barclays Conferences

Feb 25, 2026, 8:00 AM EST - 5 months ago

Charles River raises annual profit view as it sells underperforming assets

Feb 25, 2026, 7:00 AM EST - 5 months ago

Charles River Laboratories Provides Update on Planned Divestitures

Feb 18, 2026, 8:30 AM EST - 6 months ago

Charles River Laboratories International Earnings Call Transcript: Q4 2025

Feb 18, 2026, 8:30 AM EST - 6 months ago

Charles River Laboratories International Annual report: Q4 2025

Feb 18, 2026, 8:30 AM EST - 6 months ago

Charles River Laboratories International Earnings release: Q4 2025

Feb 18, 2026, 8:30 AM EST - 6 months ago

Charles River Laboratories International Slides: Q4 2025

Feb 18, 2026, 7:54 AM EST - 6 months ago

Charles River forecasts upbeat 2026 profit on improved demand for drug development services

Feb 18, 2026, 7:01 AM EST - 6 months ago

Charles River Laboratories Announces Executive Appointments

Feb 18, 2026, 7:00 AM EST - 6 months ago

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance

Feb 12, 2026, 11:54 AM EST - 6 months ago

Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Jan 21, 2026, 4:30 PM EST - 6 months ago

Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call

Jan 21, 2026, 8:00 AM EST - 7 months ago

Charles River Enters Manufacturing Collaboration with Gazi University

Jan 20, 2026, 3:39 PM EST - 7 months ago

Charles River Laboratories Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL

Jan 13, 2026, 1:30 PM EST - 7 months ago

Charles River Laboratories International Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 1:30 PM EST - 7 months ago

Charles River Laboratories International Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 5:19 PM EST - 7 months ago

Charles River to buy Cambodia-based monkey supplier for $510 million

Jan 12, 2026, 4:30 PM EST - 7 months ago

Charles River Laboratories Provides Business Updates

Jan 8, 2026, 8:00 AM EST - 7 months ago

Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan

Dec 11, 2025, 8:00 AM EST - 8 months ago

Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort

Dec 4, 2025, 8:30 AM EST - 8 months ago

T. Rowe Price Transitions to Charles River's Enterprise Multi-Asset Investment Management Platform

Dec 3, 2025, 10:00 AM EST - 8 months ago

Charles River Laboratories International Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 1, 2025, 3:42 PM EST - 8 months ago

HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Dec 1, 2025, 8:00 AM EST - 8 months ago

Charles River Laboratories to Present at Evercore Healthcare Conference

Nov 18, 2025, 8:00 AM EST - 9 months ago

SOLVE and Charles River Development Partner to Deliver Integrated Fixed Income Pricing for Investment Managers

Nov 18, 2025, 6:30 AM EST - 9 months ago

Charles River Laboratories International Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 8:00 AM EST - 9 months ago

Charles River Laboratories to Present at Jefferies Global Healthcare Conference

Nov 5, 2025, 9:00 AM EST - 9 months ago

Charles River Laboratories International Earnings Call Transcript: Q3 2025

Nov 5, 2025, 9:00 AM EST - 9 months ago

Charles River Laboratories International Quarterly report: Q3 2025

Nov 5, 2025, 9:00 AM EST - 9 months ago

Charles River Laboratories International Earnings release: Q3 2025

Nov 5, 2025, 9:00 AM EST - 9 months ago

Charles River Laboratories International Slides: Q3 2025

Nov 5, 2025, 7:34 AM EST - 9 months ago

Charles River raises annual profit forecast on stabilizing biotech demand

Nov 5, 2025, 7:01 AM EST - 9 months ago

Charles River Laboratories Provides Update on Strategic Review

Nov 5, 2025, 7:00 AM EST - 9 months ago

Charles River Laboratories Announces Third-Quarter 2025 Results

Oct 22, 2025, 8:00 AM EDT - 10 months ago

Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development

Oct 20, 2025, 8:00 AM EDT - 10 months ago

Charles River and X-Chem Announce Strategic Collaboration to Enhance Hit Identification Capabilities

Oct 15, 2025, 8:00 AM EDT - 10 months ago

Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoption

Oct 14, 2025, 8:00 AM EDT - 10 months ago

Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call

Oct 8, 2025, 8:00 AM EDT - 10 months ago

Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing

OpenOutcrier Aug. 5 at 12:35 PM

$CRL (+8.1% pre) Charles River Labs stock climbs 8% on Q2 beat, raised guidance https://ooc.bz/l/109970

0 · Reply

flychicken1991 Aug. 5 at 12:27 PM

0 · Reply

StocktwitsEarnings Aug. 5 at 11:21 AM

0 · Reply

Bloodmooncapital Aug. 5 at 1:14 AM

$CRL

0 · Reply

IN0V8 Jul. 9 at 5:32 PM

$CRL Opportunity Morgan Stanley raises PT to $260.00 from $220.00

0 · Reply

Fingerlickengood Jun. 17 at 5:33 PM

3 · Reply

briefingcom Jun. 17 at 12:43 PM

0 · Reply

Estimize May. 27 at 1:03 PM

Wall St is expecting 2.73 EPS for $CRL Q2 [Reporting 08/12 BMO] http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_cont

0 · Reply

YouOnlyLiveTwice May. 15 at 4:20 PM

$TMO $CRL What’s even more concerning besides that this space being bearish w these stocks trading at 5 year lows and NO CONSOLIDATION…

0 · Reply

YouOnlyLiveTwice May. 13 at 2:02 PM

$CRL $TMO These o my one that has growth in excess of 7% is RVTY and the only one w cloud based AI technology

0 · Reply

YouOnlyLiveTwice May. 13 at 1:59 PM

$CRL $TMO These are dead stocks .. They have NO growth ….

1 · Reply

CapitalMonk May. 13 at 3:39 AM

$CRL Price: $168.69 (+0.14%) Trend: Bearish Market Bias (7D): Sideways ⚖️ Expected Range: ±1.23% RSI: 38.3 | Momentum: Strong Downside Volume: -39.8% vs avg Volatility: 3.50% Support: $161.95 | Resistance: $194.57 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25

0 · Reply

YouOnlyLiveTwice May. 12 at 7:51 PM

$RVTY $BSX $CRL $TMO

0 · Reply

YouOnlyLiveTwice May. 11 at 3:50 PM

$CRL Nobody wants company w 1% growth when you have tech and industrials growing in double digits

0 · Reply

MarketBeat May. 9 at 11:04 PM

https://marketbeat.com/a/8644554/ $CRL Charles River Laboratories International Q1 Earnings Call Highlights

0 · Reply

StocktwitsEarnings May. 7 at 11:22 AM

$CRL Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.30 down -160.00% YoY • Reported revenue of $995.83M up 1.18% YoY • Charles River reaffirms its 2026 organic revenue guidance of (1.5)% to (0.5)% and non-GAAP EPS guidance of $10.80 to $11.30, but reduced its reported revenue outlook by approximately 50 basis points.

0 · Reply

SuperGreenToday Apr. 28 at 6:49 PM

$CRL Share Price: $165.87 Contract Selected: Aug 21, 2026 $170 Calls Buy Zone: $21.34 – $26.36 Target Zone: $35.30 – $43.14 Potential Upside: 56% ROI Time to Expiration: 114 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

YouOnlyLiveTwice Apr. 23 at 4:19 PM

$CRL All med device are sells …

0 · Reply